Updates and Ideas

Hutchison China Meditech - 17 of 307 Chinese "essential medicines"

June 2010

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

One clue to the growth potential still up ahead for Hutchison China Meditech (HCM; 245p) is the fact that in the last two decades the disposable income of China's urban and rural residents grew close to 20 times. With that has come a demand for better medicines but the problem has been that average medical costs during this time has soared more than 130 times. In April â€™09, the Chinese government launched their three-year plan for medical reform which is intended to provide access to essential health care for everyone in China by 2020 and followed this up in August with their â€œessential medicines listâ€ of 307 medicines - those that satisfy priority health needs and which are to be ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

West China Cement

Volex - Five quarters of improvement

Hutchison China Meditech -NÃ©stle deal for HMPL-004 drug (January 2013)

Hutchison China Meditech (September 2012)

Hutchison China Meditech - 2012 starts with a bang (April 2012)

Hutchison China Meditech (March 2012)

Hutchison China Meditech - Nets US$20m upfront collaboration payment from Astra Zeneca (January 2012)

Hutchison China Meditech - Broker says 600p sum of parts (September 2011)

Hutchison China Meditech - To distribute third party drugs (August 2011)

Hutchison China Meditech (April 2011)

Hutchison China Meditech - Pre-IPO funding ahead of NASDAQ float? (January 2011)

Hutchison China Meditech (October 2010)

Hutchison China Meditech - Out-licensing deal for lead product imminent (September 2010)

Hutchison China Meditech - Great secrecy shrouds R&D division (July 2010)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X